Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT04024462
What this trial is testing

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Hoffmann-La Roche 200
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Hoffmann-La Roche 210
Testing effectiveness (Phase 2)Ended earlyNCT03983395
What this trial is testing

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Ichnos Sciences SA 1
Large-scale testing (Phase 3)UnknownNCT05346861
What this trial is testing

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Fudan University 240
Testing effectiveness (Phase 2)Looking for participantsNCT07708194
What this trial is testing

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 94
Large-scale testing (Phase 3)Study completedNCT03705429
What this trial is testing

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Who this might be right for
Breast Neoplasms
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 51
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Large-scale testing (Phase 3)UnknownNCT02973737
What this trial is testing

Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 279
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Early research (Phase 1)Ended earlyNCT02571530
What this trial is testing

Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

Who this might be right for
Neoplasm Metastasis
Northwell Health 2
Not applicableActive Not RecruitingNCT03460067
What this trial is testing

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
University of Kansas Medical Center 12
Very early researchStudy completedNCT04267900
What this trial is testing

99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Peking Union Medical College Hospital 34
Testing effectiveness (Phase 2)Study completedNCT06375707
What this trial is testing

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT03379428
What this trial is testing

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsMalignant Neoplasm of Breast
US Oncology Research 34
Very early researchStudy completedNCT03132467
What this trial is testing

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+14 more
M.D. Anderson Cancer Center 16
Not applicableStudy completedNCT07829900
What this trial is testing

First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer

Who this might be right for
HER2-Positive Breast CancerAdvanced Breast Cancer
Xin Li 2,250
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Next Page